Updated
Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline
BMJ 2019; 367 doi:
https://doi.org/10.1136/bmj.l5515 (Published 02 October 2019)
https://www.bmj.com/content/367/bmj.l5515Recommendations
These recommendations apply to adults aged 50-79 years with no prior screening, no symptoms of colorectal cancer, and a life expectancy of at least 15 years. For individuals with an estimated 15-year colorectal cancer risk below 3%, we suggest no screening (weak recommendation). For individuals with an estimated 15-year risk above 3%, we suggest screening with one of the four screening options: FIT every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy (weak recommendation). With our guidance we publish the linked research, a graphic of the absolute harms and benefits, a clear description of how we reached our value judgments, and linked decision aids.
Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
BMJ 2019; 367 doi:
https://doi.org/10.1136/bmj.l5383 (Published 02 October 2019)
Conclusions
Over a 15 year period, all screening strategies may reduce colorectal cancer mortality to a similar extent. Colonoscopy and sigmoidoscopy may also reduce colorectal cancer incidence, while FIT shows a smaller incidence reduction. Harms are rare and of similar magnitude for all screening strategies.
The QCancer® 15 yr, colorectal risk calculator:
http://qcancer.org/15yr/colorectalHealth Canada Risk Calculator
https://www.mycanceriq.ca/Cancers/ColorectalIn Health
Jeff